Physician profile
Umber Burhan
NPI 1932339124
$1,490.75
in general payments reported to CMS, 2019-2025
18 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.04 · 2020: $126 · 2022: $244 · 2024: $21.67 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,031.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $395.44 | 2022-2025 | |
| Travere Therapeutics, INC. | $170.45 | 2025 | Filspari |
| Scpharmaceuticals INC. | $163.28 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $125.93 | 2020 | |
| Novartis Pharmaceuticals Corporation | $96.76 | 2025 | |
| Amgen INC. | $93.28 | 2025 | Tavneos, Krystexxa, Uplizna |
| Novo Nordisk INC | $76.92 | 2024-2025 | Rybelsus, Ozempic |
| Vifor Pharma, INC. | $65.37 | 2019-2025 | Veltassa |
| Lilly USA, LLC | $53.74 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $43.34 | 2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $32.74 | 2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.00 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $28.78 | 2025 | Lupkynis |
| Daiichi Sankyo INC. | $28.57 | 2025 | Injectafer |
| Akebia Therapeutics INC | $25.52 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $25.46 | 2025 | Empaveli |
| Alexion Pharmaceuticals, INC. | $20.55 | 2025 | Ultomiris |
| Fresenius USA Marketing, INC. | $15.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umber Burhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.